// App-Quantinova.ai

TPS1135 : An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.

Researchers

Presenter

  • Tiffany P. Avery

Principal Investigators

  • Adam C. Berger

  • Edith P. Mitchell

  • Albert J. Kovatich

  • Hallgeir Rui

  • Terry Hyslop

Medical Centers

  • MDR Global Systems, Windber, PA

  • Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PAJefferson Medical College of Thomas Jefferson University, Philadelphia, PADepartment of Surgery, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

  • Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

  • Cytokeratin 5

  • Epidermal growth factor receptor

  • Excision repair cross-complementation group 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pegfilgrastim

  • Carboplatin

  • Doxorubicin

  • Filgrastim

  • Paclitaxel

  • Veliparib

Outcome

  • N/A

Study Design

  • randomized

  • adaptive

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved